For a patient with hypertension, which medication—lisinopril or benazepril—is preferred, considering efficacy, need for hepatic activation, and dosing?

Lisinopril vs Benazepril for Hypertension

For patients with hypertension, lisinopril is preferred over benazepril because it does not require hepatic activation, making it more reliable in patients with liver disease, and it has more robust clinical trial evidence demonstrating cardiovascular outcomes benefits.

Key Pharmacological Distinction

The fundamental difference between these two ACE inhibitors lies in their activation:

• Lisinopril is a biologically active drug that works immediately upon absorption without requiring metabolic conversion 11
• Benazepril is a prodrug that must be converted to benazeprilat in the liver to become active 2

This distinction has critical clinical implications. Research directly comparing ACE inhibitors in patients with hepatic cirrhosis demonstrated that lisinopril showed superior blood pressure reduction compared to enalapril (another prodrug requiring hepatic activation) in hypertensive patients with liver disease 3. While this study didn't include benazepril specifically, the principle applies: prodrugs requiring hepatic metabolism are less predictable in patients with any degree of hepatic impairment.

Clinical Evidence Base

Lisinopril's Superior Evidence

Lisinopril has substantially more robust outcomes data:

• GISSI-3 trial: Demonstrated mortality reduction and prevention of left ventricular dysfunction post-myocardial infarction in over 50,000 patients 4
• ALLHAT trial: Chlortalidone was compared to lisinopril in a massive outcomes trial, establishing lisinopril as a reference ACE inhibitor 5
• Multiple trials in heart failure, diabetic nephropathy, and post-MI settings with hard cardiovascular endpoints 14

Benazepril's Limited Evidence

Benazepril has far less robust outcomes data:

• Studies primarily focus on blood pressure reduction as a surrogate endpoint 26
• Efficacy appears equivalent to other ACE inhibitors for BP lowering, but lacks the extensive cardiovascular outcomes trials that lisinopril possesses 2

Dosing Considerations

Lisinopril offers more straightforward dosing:

• Initial dose: 10 mg once daily for most patients 1
• Range: 20-40 mg daily (up to 80 mg studied) 1
• Once-daily dosing is standard, though some evidence suggests twice-daily dosing may provide superior BP control in select patients 7
• Clear renal dosing adjustments provided 1

Benazepril dosing:

• Requires 20 mg daily to match hydrochlorothiazide efficacy; lower doses (2,5,10 mg) showed no significant benefit over placebo 6
• Less extensive dosing data in special populations 2

Guideline Context

Current major guidelines (2024 ESC, 2025 AHA/ACC) recommend ACE inhibitors as first-line agents for hypertension but do not distinguish between individual ACE inhibitors 88. They emphasize:

• ACE inhibitors (or ARBs) combined with CCBs or thiazide diuretics as preferred initial therapy 88
• Single-pill combinations to improve adherence 8

However, when selecting a specific ACE inhibitor, the evidence hierarchy favors agents with proven outcomes benefits beyond blood pressure reduction.

Clinical Algorithm for Selection

Choose lisinopril when:

• Any degree of hepatic impairment or concern about liver function
• Seeking an ACE inhibitor with the most robust cardiovascular outcomes data
• Patient requires renal dosing adjustments (well-established protocols) 1
• Post-MI, heart failure, or diabetic nephropathy (extensive trial data) 14

Benazepril might be considered when:

• Lisinopril is not tolerated (though adverse effect profiles are similar across ACE inhibitors)
• Formulary restrictions mandate its use

Important Caveats

• Both drugs cause cough at similar rates (class effect of ACE inhibitors) 9
• Both require monitoring for hyperkalemia, renal function, and hypotension 1
• In patients with significant renal impairment (CrCl <30 mL/min), lisinopril requires dose reduction to 2.5-5 mg daily 1
• Black patients may have reduced response to ACE inhibitor monotherapy; combination with a thiazide diuretic or CCB is often necessary 11

The biological activity of lisinopril without hepatic metabolism requirement, combined with its extensive cardiovascular outcomes evidence base, makes it the more reliable and evidence-supported choice between these two ACE inhibitors 345.